Cardiovascular Journal of Africa: Vol 25 No 2(March/April 2014) - page 4

financial & production
co-ordinator
ELSABÉ BURMEISTER
Tel: 021 976 8129
Fax: 086 664 4202
Cell: 082 775 6808
e-mail:
Production Editor
SHAUNA GERMISHUIZEN
Tel: 021 785 7178
Fax: 086 628 1197
e-mail:
CONTENT MANAGER
Michael Meadon (Design
Connection)
Tel: 021 976 8129
Fax: 0866 557 149
e-mail:
GAUTENG CONTRIBUTOR
PETER WAGENAAR
Cell 082 413 9954
e-mail:
The
Cardiovascular Journal of Africa
,
incorporating the
Cardiovascular
Journal of South Africa
, is published 10
times a year, the publication date being
the third week of the designated month.
Copyright:
Clinics Cardive Publishing (Pty) Ltd.
Layout:
Martingraphix
Printer:
Durbanville Commercial Printers/
Tandym Print
ONLINE SERVICES:
Design Connection
All submissions to CVJA are to be
made online via
Electronic submission by means of an
e-mail attachment may be considered
under exceptional circumstances.
Postal address: PO Box 1013,
Durbanville, RSA, 7551
Tel: 021 976 8129
Fax: 0866 644 202
Int.: +27 21 976 8129
e-mail:
Electronic abstracts available on Pubmed
Audited circulation
Full text articles available on:
.
co.za or via
; for access
codes contact
Subscriptions for 10 issues:
To subscribe to the journal or change
your postal address, e-mail
South Africa: R650 (excl VAT)
Overseas: R1306
Online subscription: R200
The views and opinions expressed in the
articles and reviews published are those
of the authors and do not necessarily
reflect those of the editors of the Journal
or its sponsors. In all clinical instances,
medical practitioners are referred to the
product insert documentation as approved
by the relevant control authorities.
CONTENTS
Vol 25, No 2, MARCH/APRIL 2014
Review Article
83 Optimal utilisation of sulphonylureas in resource-constrained settings
P Naidoo • V Rambiritch • N Butkow • S Saman
Letter to the Editor
86 Adverse effects of ethyl esters or oxidation products in omega-3 preparations?
H Rupp • KG Rupp
Drug Trends
88
Cryoballoon ablation for atrial fibrillation is now possible in South Africa
Anne Hahn
90 Bayer’s Xarelto
®
is approved in South Africa across five additional indications
PUBLISHED ONLINE
(Available on
and in Pubmed)
Case Report
e1 Unusual perforation of the left ventricle during radiofrequency catheter ablation for
ventricular tachycardia
J-T Wu • J-Z Dong
1,2,3 5,6,7,8,9,10,11,12,13,14,...60
Powered by FlippingBook